CIBC Asset Management
RVNC

CIBC Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

CIBC Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,740,518
Closed -$8.56M – 1221
2024
Q1 		$8.56M Buy
1,740,518
+593,224
+52% +$3.51M 0.03% 304
2023
Q4 		$10.1M Buy
1,147,294
+820,587
+251% +$6.72M 0.04% 251
2023
Q3 		$3.75M Buy
326,707
+93,701
+40% +$1.8M 0.02% 408
2023
Q2 		$5.9M Buy
233,006
+6,338
+3% +$197K 0.02% 338
2023
Q1 		$7.3M Sell
226,668
-185,169
-45% -$5.77M 0.03% 297
2022
Q4 		$7.6M Sell
411,837
-89,332
-18% -$2.04M 0.03% 279
2022
Q3 		$13.5M Buy
+501,169
New +$10.2M 0.06% 179
2022
Q2 		– Sell
-470,819
Closed -$9.18M – 1501
2022
Q1 		$9.18M Sell
470,819
-27,410
-6% -$416K 0.03% 254
2021
Q4 		$8.13M Buy
+498,229
New +$8.31M 0.03% 292

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIBC Asset Management's RVNC Position: Q2 2024 in Review

CIBC Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 1,740,518 shares — an estimated $8.56M sold.

CIBC Asset Management first reported a position in RVNC in Q4 2021 and held it in 9 quarters. The position peaked at $13.5M in Q3 2022. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • CIBC Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • CIBC Asset Management sold 1,740,518 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $8.56M.
  • CIBC Asset Management first reported a position in Revance Therapeutics, Inc. in Q4 2021 and held it in 9 quarters.
  • CIBC Asset Management's Revance Therapeutics, Inc. position peaked at $13.5M in Q3 2022.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on CIBC Asset Management's 13F filing for Q2 2024, filed 1 Aug 2024.